{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T07:30:10Z","timestamp":1793950210169,"version":"4.8.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019211","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019211","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Treatment options for paediatric patients with psoriasis are limited, and additional, more advanced therapies are needed. Risankizumab is an interleukin-23 inhibitor approved to treat moderate-to-severe psoriasis in adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate efficacy and safety of risankizumab through 52 weeks in paediatric patients with moderate-to-severe psoriasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>OptIMMize-1 (Clinical Trial Registration NCT04435600) was a phase III, multicentre, four-part study. Parts 1, 3 and 4 were 52-week, open-label studies. Part 2 consisted of a 16-week initial treatment period (Period A; 2 : 1 risankizumab: ustekinumab randomization), followed by up to 36-week randomized treatment or withdrawal period (Period B) for patients whose disease responded to risankizumab, with a potential 16-week retreatment period (Period C) for patients who experienced a disease flare. Patients whose disease did not respond to risankizumab and patients randomized to ustekinumab in Period A received risankizumab during Period B. Key outcomes were a static Physician\u2019s Global Assessment (sPGA) score of clear or almost clear (sPGA 0\/1), sPGA 0 or 1 with \u2265 2-grade improvement (sPGA 0\/1 + \u2265 2GI) or achievement of \u2265 75%, \u2265 90% or 100% improvement in Psoriasis Area and Severity Index (PASI 75\/90\/100). The study also assessed itch severity, quality of life and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 137 patients enrolled. In Part 2 (risankizumab, n = 54; ustekinumab, n = 28), week 16 response rates were similar: sPGA 0\/1 was 80% (n = 43\/54) for risankizumab and 75% (n = 21\/28) for ustekinumab; sPGA 0\/1 + \u2265 2GI rates were 69% (n = 37\/54) vs. 68% (n = 19\/28); PASI 75 rates were 85% (n = 46\/54) vs. 86% (n = 24\/28); and PASI 90 rates were 65% (n = 35\/54) vs. 61% (n = 17\/28). PASI 100 responses were higher with risankizumab (41%, n = 22\/54) than with ustekinumab (18%, n = 5\/28). In Part 4 (n = 30), week 16 rates were sPGA 0\/1: 90% (n = 27\/30), sPGA 0\/1 + \u2265 2GI: 83% (n = 25\/30), PASI 75: 87% (n = 26\/30), PASI 90: 77% (n = 23\/30) and PASI 100: 43% (n = 13\/30); week 52 responses were maintained or improved. Skin clearance outcomes in Parts 1 and 3 were consistent with those observed with continuous risankizumab treatment in Parts 2 and 4. Improvements in itch and quality of life (assessed in Part 2 only) were observed at weeks 16 and 52. Risankizumab safety profiles were consistent with those observed in prior adult psoriasis studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Risankizumab was well tolerated in paediatric patients, with marked improvements in skin clearance, itching and quality of life. Efficacy was maintained or improved at week 52, supporting risankizumab use for moderate-to-severe psoriasis in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjd\/ljag403","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:25:41Z","timestamp":1789755941000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of risankizumab in paediatric patients with psoriasis in the OptIMMize-1 phase III study"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6802-0153","authenticated-orcid":false,"given":"Nina","family":"Magnolo","sequence":"first","affiliation":[{"name":"Department of Dermatology, University Hospital M\u00fcnster , M\u00fcnster ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Wine Lee","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina , Charleston, SC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Reich","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Faculty of Medicine, Medical College, University of Rzesz\u00f3w , Rzesz\u00f3w ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Lara-Corrales","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Division of Dermatology, The Hospital for Sick Children , Toronto, ON ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8372-3754","authenticated-orcid":false,"given":"Akimichi","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Geriatric and Environmental Dermatology, Nagoya City University , Nagoya ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bukhalo","sequence":"additional","affiliation":[{"name":"Arlington Dermatology , Rolling Meadows, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asunci\u00f3n","family":"Vicente","sequence":"additional","affiliation":[{"name":"Department of Pediatric Dermatology, Hospital Sant Joan de D\u00e9u , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Anschutz","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosie D","family":"Lyles","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tshepiso","family":"Madihlaba","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Unnebrink","sequence":"additional","affiliation":[{"name":"AbbVie Deutschland GmbH & Co. KG , Ludwigshafen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doug","family":"Ashley","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolly","family":"Sharma","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronilda","family":"D\u2019Cunha","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S","family":"Paller","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Northwestern University Feinberg School of Medicine , Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,26]]},"reference":[{"key":"2026110602212940700_ljag403-B1","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s40272-015-0137-1","article-title":"Psoriasis in children and adolescents: diagnosis, management and comorbidities","volume":"17","author":"Bronckers","year":"2015","journal-title":"Paediatr Drugs"},{"key":"2026110602212940700_ljag403-B2","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00403-025-03862-3","article-title":"Challenges in diagnosis and treatment of pediatric psoriasis and atopic dermatitis","volume":"317","author":"Patra","year":"2025","journal-title":"Arch Dermatol Res"},{"key":"2026110602212940700_ljag403-B3","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1080\/09546634.2022.2059051","article-title":"Managing pediatric psoriasis: update on treatments and challenges-a review","volume":"33","author":"Hebert","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"2026110602212940700_ljag403-B4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-025-00630-5","article-title":"Psoriasis","volume":"11","author":"Armstrong","year":"2025","journal-title":"Nat Rev Dis Primers"},{"key":"2026110602212940700_ljag403-B5","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/1346-8138.17049","article-title":"Pediatric psoriasis: understanding pathological conditions and advances in treatment","volume":"51","author":"Morita","year":"2024","journal-title":"J Dermatol"},{"key":"2026110602212940700_ljag403-B6","doi-asserted-by":"crossref","first-page":"11128","DOI":"10.3390\/ijms231911128","article-title":"Biological treatments for pediatric psoriasis: state of the art and future perspectives","volume":"23","author":"Diotallevi","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026110602212940700_ljag403-B7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/bjd.17198","article-title":"Highlights of the updated Dutch evidence- and consensus-based guideline on psoriasis 2017","volume":"180","author":"van der Kraaij","year":"2019","journal-title":"Br J Dermatol"},{"key":"2026110602212940700_ljag403-B8","first-page":"959","article-title":"S2k guidelines for the treatment of psoriasis in children and adolescents - short version part 2","volume":"17","author":"Eisert","year":"2019","journal-title":"J Dtsch Dermatol Ges"},{"key":"2026110602212940700_ljag403-B9","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1007\/s13555-022-00758-2","article-title":"Update on the management of pediatric psoriasis: an Italian consensus","volume":"12","author":"Peris","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026110602212940700_ljag403-B10","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.4103\/idoj.IDOJ_965_20","article-title":"Recommendations for management of childhood psoriasis","volume":"12","author":"Katakam","year":"2021","journal-title":"Indian Dermatol Online J"},{"key":"2026110602212940700_ljag403-B11","doi-asserted-by":"crossref","first-page":"T254","DOI":"10.1016\/j.ad.2024.12.015","article-title":"[Translated article] Consensus Statement from the Spanish Academy of Dermatology and Venereology (AEDV) Psoriasis Working Group (SWG) and Pediatric Working Group (PWG) on the Management of Pediatric Psoriasis","volume":"116","author":"Vicente","year":"2025","journal-title":"Actas Dermosifiliogr"},{"key":"2026110602212940700_ljag403-B12","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/j.jaad.2025.02.023","article-title":"Investigation of the applicability of adult definitions of disease severity for psoriasis in a pediatric cohort: a prospective registry study","volume":"92","author":"Al-Gawahiri","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"2026110602212940700_ljag403-B13","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1007\/s13555-022-00761-7","article-title":"Patient characteristics and treatment patterns in European pediatric patients with psoriasis: a real-world, cross-sectional study","volume":"12","author":"Sticherling","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026110602212940700_ljag403-B14","doi-asserted-by":"crossref","first-page":"847308","DOI":"10.3389\/fphar.2022.847308","article-title":"Efficacy of systemic biologic drugs in pediatric psoriasis: evidence from five selected randomized clinical trials","volume":"13","author":"Di Lernia","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026110602212940700_ljag403-B15","author":"Skyrizi (risankizumab-rzaa)"},{"key":"2026110602212940700_ljag403-B16","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"2026110602212940700_ljag403-B17","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s40257-025-00964-6","article-title":"Long-term safety and efficacy of risankizumab to treat moderate-to-severe plaque psoriasis: final LIMMitless phase 3, open-label extension trial results","volume":"26","author":"Papp","year":"2025","journal-title":"Am J Clin Dermatol"},{"key":"2026110602212940700_ljag403-B18","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jaad.2023.08.097","article-title":"Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry","volume":"90","author":"Strober","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"2026110602212940700_ljag403-B19","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s13555-025-01342-0","article-title":"Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis: interim analysis from the VALUE global prospective post-marketing observational study at 25\u2005months","volume":"15","author":"Tha\u00e7i","year":"2025","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026110602212940700_ljag403-B20","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s40262-019-00759-z","article-title":"Population pharmacokinetics of risankizumab in healthy volunteers and subjects with moderate to severe plaque psoriasis: integrated analyses of phase I-III clinical trials","volume":"58","author":"Suleiman","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"2026110602212940700_ljag403-B21","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.clinthera.2021.01.009","article-title":"Pharmacokinetic comparability of risankizumab formulations in prefilled syringe and auto-injector for subcutaneous injection","volume":"43","author":"Lon","year":"2021","journal-title":"Clin Ther"},{"key":"2026110602212940700_ljag403-B22","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(22)00467-6","article-title":"Risankizumab as induction therapy for Crohn\u2019s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials","volume":"399","author":"D\u2019Haens","year":"2022","journal-title":"Lancet"},{"key":"2026110602212940700_ljag403-B23","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1007\/s13555-024-01238-5","article-title":"Long-term safety of risankizumab in patients with psoriatic disease: a comprehensive analysis from clinical trials","volume":"14","author":"Gordon","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026110602212940700_ljag403-B24","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1001\/jamadermatol.2019.3717","article-title":"Association between quality of life and improvement in psoriasis severity and extent in pediatric patients","volume":"156","author":"Bruins","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2026110602212940700_ljag403-B25","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s40272-022-00507-0","article-title":"Efficacy of secukinumab across subgroups and overall safety in pediatric patients with moderate to severe plaque psoriasis: week 52 results from a phase III randomized study","volume":"24","author":"Magnolo","year":"2022","journal-title":"Paediatr Drugs"},{"key":"2026110602212940700_ljag403-B26","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/bjd\/ljae502","article-title":"Guselkumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients: results of the phase III randomized placebo-controlled PROTOSTAR study","volume":"192","author":"Prajapati","year":"2025","journal-title":"Br J Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljag403\/71400088\/ljag403.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljag403\/71400088\/ljag403.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T07:21:38Z","timestamp":1793949698000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article\/doi\/10.1093\/bjd\/ljag403\/8836367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,26]]},"references-count":26,"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljag403","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,26]]},"article-number":"ljag403"}}